Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00045149 · ClinicalTrials.gov registry record · Phase 1

Biological Therapy in Treating Patients With Metastatic Melanoma

A Phase 1 study of Melanoma (Skin), sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00045149 is a Phase 1 study of Melanoma (Skin) that has completed, run by Fred Hutchinson Cancer Center. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00045149, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Conditions Studied

Melanoma (Skin)

Interventions

  • BIOLOGICAL aldesleukin
  • BIOLOGICAL therapeutic tumor infiltrating lymphocytes

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Start Date 2002-10
Est. Completion 2005-06
Phase Phase 1

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00045149

The ClinicalTrials.gov registry entry for NCT00045149 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which aldesleukin is the first listed.

NCT00045149 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00045149 about?

NCT00045149 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cell...

What is the current status of trial NCT00045149?

This trial is currently completed. It is a Phase 1 study. The study started on 2002-10. Estimated completion is 2005-06.

What conditions does trial NCT00045149 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT00045149?

The interventions under investigation include: aldesleukin (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL).

Who is sponsoring clinical trial NCT00045149?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00045149 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma (Skin)

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.